Ars Pharmaceuticals Expands $199 Retail Access Program Amid Anticipation for CVS Caremark Decision

Ars Pharmaceuticals (NASDAQ:SPRY) is expanding its retail access program, offering neffy at a price of $199 per month. The company's CEO highlighted efforts to increase affordability and prescriber adoption while awaiting a decision from CVS Caremark.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · May 16, 2026, 01:32 UTC

Tickers: $SPRY

Topics: access expansion business strategy pharmaceuticals

Read the full article at Seeking Alpha

More World news

Zenta Group Receives Nasdaq Notice Regarding Minimum Bid Price Requirement Seeking Alpha · November 12, 2026, 13:48 UTC
SoLo Funds Launches SoLo Alpha High-Yield Investment Account PR Newswire · November 12, 2026, 13:50 UTC
Artelo Biosciences Reports Third Quarter GAAP EPS of -$3.19 Seeking Alpha · November 12, 2026, 13:46 UTC
Monopar Therapeutics Reports Q3 GAAP EPS of -$0.72 in Line with Expectations Seeking Alpha · November 12, 2026, 13:48 UTC
Market Watch: Nvidia Pressure and Key Stocks NBIS, GOOG, GIS, and MANU Seeking Alpha · November 12, 2026, 13:48 UTC
Chevron Reports $10.4 Billion Third Quarter Profit Driven by High Refining Margins Motley Fool · November 12, 2026, 13:43 UTC
Replay Sports Cards Expands North Carolina Presence with New Greenville Location PR Newswire · November 12, 2026, 13:47 UTC
Linnworks Survey Reveals US E-commerce Businesses Limit AI Role to Operational Support Over Financial Control PR Newswire · November 12, 2026, 13:43 UTC
DocsInk Rebrands as TraceWell Health and Launches Integrated Care Platform PR Newswire · November 12, 2026, 13:44 UTC
Zoom Ventures Invests in Medaica to Advance AI-Powered Virtual Healthcare Seeking Alpha · November 12, 2026, 13:40 UTC